A new class of HIV-1 protease inhibitors containing a tertiary alcohol in the transition-state mimicking scaffold

Journal of Medicinal Chemistry

Volumn 48, Issue 25, 2005, Pages 8098-8102

  Ekegren, Jenny K ^a   Unge, Torsten ^a   Safa, Mayada Zreik ^a   Wallberg, Hans ^b   Samuelsson, Bertil ^b   Hallberg, Anders ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b MEDIVIR AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL DERIVATIVE; ANTIRETROVIRUS AGENT; ATAZANAVIR; HYDROXYL GROUP; INDINAVIR; PROTEINASE INHIBITOR;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BIOASSAY; CONTROLLED STUDY; DRUG POTENCY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROGEN BOND; IN VITRO STUDY; LIPOPHILICITY; NONHUMAN; STEREOCHEMISTRY; X RAY CRYSTALLOGRAPHY;

ALCOHOLS; CELL LINE; CELL MEMBRANE PERMEABILITY; CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE, VIRAL; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MOLECULAR CONFORMATION; MOLECULAR MIMICRY; MUTATION; STEREOISOMERISM;

EID: 29144501184     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050790t     Document Type: Article

References (39)

1. Barre-Sinoussi, F.; Chermann, J. C.; Rey, F.; Nugeyre, M. T.; Chamaret, S.; Gruest, J.; Dauguet, C.; Axler-Blin, C.; Vezinet-Brun, F.; Rouzioux, C.; Rozenbaum, W.; Montagnier, L. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983, 220, 868-871.
2. Gallo, R. C.; Sarin, P. S.; Gelmann, E. P.; Robert-Guroff, M.; Richardson, E.; Kalyanaraman, V. S.; Mann, D.; Sidhu, G. D.; Stahl, R. E.; Zolla-Pazner, S.; Leibowitch, J.; Popovic, M. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 1983, 220, 865-867.
3. AIDS Epidemic Update: December 2004; Joint United Nations Programme on HIV/AIDS (UNAIDS)/WHO, 2004.
4. Pomerantz, R. J.; Horn, D. L. Twenty years of therapy for HIV-1 infection. Nat. Med. 2003, 9, 867-873.
5. Peterlin, B. M.; Trono, D. Hide, shield and strike back: how HIV-infected cells avoid immune eradication. Nat. Rev. Immunol. 2003, 3, 97-107.
6. 2004 Report on the Global AIDS Epidemic; Joint United Nations Programme on HIV/AIDS (UNAIDS), 2004.
7. Clavel, F.; Hance, A. J. HIV drug resistance. N. Engl. J. Med. 2004, 350, 1023-1035.
8. Werber, Y. HIV drug market. Nat. Rev. Drug Discovery 2003, 2, 513-514.
9. Menéndez-Arias, L. Targeting HIV: antiretroviral therapy and development of drug resistance. Trends Pharmacol. Sci. 2002, 23, 381-388.
10. de Mendoza, C.; Soriano, V. Resistance to HIV protease inhibitors: mechanisms and clinical consequences. Curr. Drug Metab. 2004, 5, 321-328.
11. De Clercq, E. New approaches toward anti-HIV chemotherapy. J. Med. Chem. 2005, 48, 1297-1313.
12. Abdel-Rahman, H. M.; Al-Karamany, G. S.; El-Koussi, N. A.; Youssef, A. F.; Kiso, Y. HIV protease inhibitors: peptidomimetic drugs and future perspectives. Curr. Med. Chem. 2002, 9, 1905-1922.
13. Randolph, J. T.; DeGoey, D. A. Peptidomimetic inhibitors of HIV protease. Curr. Top. Med. Chem. 2004, 4, 1079-1095.
14. Rodríguez-Barrios, F.; Gago, F. HIV protease inhibition: limited recent progress and advances in understanding current pitfalls. Curr. Top. Med. Chem. 2004, 4, 991-1007.
15. Bursavich, M. G.; Rich, D. H. Designing non-peptide peptidomimetics in the 21st century: inhibitors targeting conformational ensembles. J. Med. Chem. 2002, 45, 541-558.
16. Carr, A. Toxicity of antiretroviral therapy and implications for drug development. Nat. Rev. Drug Discovery 2003, 2, 624-634.
17. Fässler, A.; Bold, G.; Capraro, H.-G.; Cozens, R.; Mestan, J.; Poncioni, B.; Rösel, J.; Tintelnot-Blomley, M.; Lang, M. Azapeptide analogs as potent human immunodeficiency virus type-1 protease inhibitors with oral bioavailability. J. Med. Chem. 1996, 39, 3203-3216.
18. Bold, G.; Fässler, A.; Capraro, H.-G.; Cozens, R.; Klimkait, T.; Lazdins, J.; Mestan, J.; Poncioni, B.; Rösel, J.; Stover, D.; Tintelnot-Blomley, M.; Acemoglu, F.; Beck, W.; Boss, E.; Eschbach, M.; Hurlimann, T.; Masso, E.; Roussel, S.; Ucci-Stoll, K.; Wyss, D.; Lang, M. New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development. J. Med. Chem. 1998, 41, 3387-3401.
19. Wang, F.; Ross, J. Atazanavir: a novel azapeptide inhibitor of HIV-1 protease. Formulary 2003, 38, 691-702.
20. Raja, A.; Lebbos, J.; Kirkpatrick, P. Fresh from the pipeline: Atazanavir sulphate. Nat. Rev. Drug Discovery 2003, 2, 857-858.
21. Rich, D. H.; Bernatowicz, M. S.; Agarwal, N. S.; Kawai, M.; Salituro, F. G.; Schmidt, P. G. Inhibition of aspartic proteases by pepstatin and 3-methylstatine derivatives of pepstatin. Evidence for collected-substrate enzyme inhibition. Biochemistry 1985, 24, 3165-3173.
22. Rich, D. H. Pepstatin-derived inhibitors of aspartic proteinases. A close look at an apparent transition-state analog inhibitor. J. Med. Chem. 1985, 28, 263-273.
23. Agarwal, N. S.; Rich, D. H. Inhibition of cathepsin D by substrate analogs containing statine and by analogs of pepstatin. J. Med. Chem. 1986, 29, 2519-2524.
24. Godfrey, J. D., Jr.; Gordon, E. M.; Von Langen, D. J. Synthesis of peptide-derived amino alcohols II. Synthetic methodology for the preparation of tertiary alcohols. Tetrahedron Lett. 1987, 28, 1603-1606.
25. Kim, B. M.; Guare, J. P.; Hanifin, C. M.; Arford-Bickerstaff, D. J.; Vacca, J. P.; Ball, R. G. A convergent synthesis of novel conformationally restricted HIV-1 protease inhibitors. Tetrahedron Lett. 1994, 35, 5153-5156.
26. Ashwood, V. A.; Field, M. J.; Horwell, D. C.; Julien-Larose, C.; Lewthwaite, R. A.; McCleary, S.; Pritchard, M. C.; Raphy, J.; Singh, L. Utilization of an intramolecular hydrogen bond to increase the CNS penetration of an NK1 receptor antagonist. J. Med. Chem. 2001, 44, 2276-2285.
27. Lyle, T. A.; Wiscount, C. M.; Guare, J. P.; Thompson, W. J.; Anderson, P. S.; Darke, P. L.; Zugay, J. A.; Emini, E. A.; Schleif, W. A.; Quintero, J. C.; Dixon, R. A. F.; Sigal, I. S.; Huff, J. R. Benzocycloalkyl amines as novel C-termini for HIV protease inhibitors. J. Med. Chem. 1991, 34, 1228-1230.
28. Askin, D.; Eng, K. K.; Rossen, K.; Purick, R. M.; Wells, K. M.; Volante, R. P.; Reider, P. J. Highly diastereoselective reaction of a chiral, non-racemic amide enolate with (S)-glycidyl tosylate. Synthesis of the orally active HIV-1 protease inhibitor L-735,524. Tetrahedron Lett. 1994, 35, 673-676.
29. Dorsey, B. D.; Levin, R. B.; McDaniel, S. L.; Vacca, J. P.; Guare, J. P.; Darke, P. L.; Zugay, J. A.; Emini, E. A.; Schleif, W. A.; Quintero, J. C.; Lin, J. H.; Chen, I.-W.; Holloway, M. K.; Fitzgerald, P. M. D.; Axel, M. G.; Ostovic, D.; Anderson, P. S.; Huff, J. R. L-735,524: The design of a potent and orally bioavailable HIV protease inhibitor. J. Med. Chem. 1994, 37, 3443-3451.
30. Liu, X.; Hu, E.; Tian, X.; Mazur, A.; Ebetino, F. H. Enantioselective synthesis of phosphinyl peptidomimetics via an asymmetric Michael reaction of phosphinic acids with acrylate derivatives. J. Organomet. Chem. 2002, 646, 212-222.
31. Sham, H. L.; Zhao, C.; Stewart, K. D.; Betebenner, D. A.; Lin, S.; Park, C. H.; Kong, X.-P.; Rosenbrook, W., Jr.; Herrin, T.; Madigan, D.; Vasavanonda, S.; Lyons, N.; Molla, A.; Saldivar, A.; Marsh, K. C.; McDonald, E.; Wideburg, N. E.; Denissen, J. F.; Robins, T.; Kempf, D. J.; Plattner, J. J.; Norbeck, D. W. A novel, picomolar inhibitor of human immunodeficiency virus type 1 protease. J. Med. Chem. 1996, 39, 392-397.
32. Savin, V. I. N-Nitrenes. IV. Synthesis of unsymmetrical bibenzyls. Zh. Org. Khim. 1992, 28, 43-50.
33. Otteneder, M.; Plastaras, J. P.; Marnett, L. J. Reaction of malondialdehyde-DNA adducts with hydrazines-development of a facile assay for quantification of malondialdehyde equivalents in DNA. Chem. Res. Toxicol. 2002, 15, 312-318.
34. 4. Reliable C-3 selectivity. J. Org. Chem. 1985, 50, 1560-1563.
35. 4-mediated nucleophilic openings of 2,3-epoxy alcohols. A mild procedure for regioselective ring-opening. J. Org. Chem. 1985, 50, 1557-1560.
36. Alterman, M.; Bjoersne, M.; Muehlman, A.; Classon, B.; Kvarnstroem, I.; Danielson, H.; Markgren, P.-O.; Nillroth, U.; Unge, T.; Hallberg, A.; Samuelsson, B. Design and synthesis of new potent C2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold. J. Med. Chem. 1998, 41, 3782-3792.
37. Balani, S. K.; Arison, B. H.; Mathai, L.; Kauffman, L. R.; Miller, R. R.; Stearns, R. A.; Chen, I. W.; Lin, J. H. Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine. Drug Metab. Dispos. 1995, 23, 266-270.
38. Molla, A.; Vasavanonda, S.; Kumar, G.; Sham, H. L.; Johnson, M.; Grabowski, B.; Denissen, J. F.; Kohlbrenner, W.; Plattner, J. J.; Leonard, J. M.; Norbeck, D. W.; Kempf, D. J. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology 1998, 250, 255-262.
39. Carrell, H. L.; Glusker, J. P.; Piercy, E. A.; Stallings, W. C.; Zacharias, D. E.; Davis, R. L.; Astbury, C.; Kennard, C. H. L. Metal chelation versus internal hydrogen bonding of the α-hydroxy carboxylate group. J. Am. Chem. Soc. 1987, 109, 8067-8071.